An Exploratory Phase II Study to Demonstrate the Safety and Efficacy of A4250 in Children With Cholestatic Pruritus

Trial Profile

An Exploratory Phase II Study to Demonstrate the Safety and Efficacy of A4250 in Children With Cholestatic Pruritus

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2018

At a glance

  • Drugs A 4250 (Primary)
  • Indications Alagille syndrome; Biliary atresia; Cholestasis; Intrahepatic cholestasis; Pruritus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Albireo AB
  • Most Recent Events

    • 14 Apr 2018 Results published in the Albireo Pharma Media Release
    • 14 Apr 2018 According to an Albireo Pharma media release, results were presented at the European Association for the Study of the Liver (EASL) The International Liver Congress 2018
    • 28 Mar 2018 According to an Albireo Pharma media release, new data from the trial will be presented at the European Association for the Study of the Liver (EASL) The International Liver Congress 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top